Back to top

Analyst Blog

Actavis, Inc. (ACT - Analyst Report), and Valeant Pharmaceuticals International, Inc.’s (VRX - Snapshot Report) Medicis Pharmaceutical Corporation recently entered into settlement agreements regarding a couple of  Abbreviated New Drug Applications (ANDAs) filed by Actavis.

Actavis had filed ANDAs seeking US Food and Drug Administration (FDA) approval for its generic versions of Valeant’s Ziana and Zyclara.

According to the terms of the settlement agreements, Actavis can now launch its generic versions of Ziana and Zyclara in Jul 2016 and on Jan 1, 2019, respectively. Actavis may, however, launch its product earlier under certain circumstances. While Ziana is approved for the topical treatment of acne vulgaris in patients 12 years or older, Zyclara is prescribed for the treatment of actinic keratosis on the full face or balding scalp in adults with a normal immune function.

Although detailed financial terms were not available, the companies said that Valeant will be entitled to a share of the economics from the generic products sold by Actavis under these agreements.

This is the second deal to be signed by Actavis and Valeant this month. Earlier, the company had entered into an agreement whereby Actavis will exclusively market and distribute an authorized generic of Valeant's Zovirax ointment.

Actavis also gained exclusive rights to co-promote Zovirax cream to obstetricians and gynecologists in the US by using its existing Specialty Brands sales and marketing structure.

In return, Valeant gained exclusive right to co-promote Actavis’ Cordran Tape in the US, which is indicated for treating inflammation and itching caused by skin allergic reactions, eczema and psoriasis. Valeant will co-promote the drug using its dermatalogy sales and marketing structure for a co-promotion fee on sales.

Actavis also settled its patent litigation with AstraZeneca (AZN - Analyst Report) regarding Crestor tablets (5, 10, 20 and 40 mg). Crestor is slated to lose exclusivity in the US on Jul 8, 2016 (including pediatric exclusivity). As per the terms of the agreement, Actavis may launch its generic version of Crestor 67 days before Crestor loses exclusivity on paying 39% of net sales to AstraZeneca.

Actavis currently holds a Zacks Rank #3 (Hold). Mylan (MYL - Analyst Report) currently looks attractive with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%